Reducing macrophage recruitment by silencing chemokine (C-C motif) receptor 2 (CCR2) expression is a promising therapeutic approach against atherosclerosis. This study investigated the feasibility of EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (ENPs) as a carrier for targeted delivery of CCR2-shRNA to atherosclerotic macrophage cellular models. Results showed enhanced ENP uptake compared to common PLGA nanoparticles. CCR2-shRNA-loaded ENPs effectively silenced CCR2 gene expression in atherosclerotic macrophages with a favorable cytotoxic profile. ENPs show potential as carriers for targeted CCR2-shRNA delivery in atherosclerosis therapy.
Publisher
Scientific Reports
Published On
Oct 26, 2020
Authors
Zhilin Wu, Chen Chen, Jiajia Luo, Jacques R. J. Davis, Bo Zhang, Liang Tang, Wei Shi, Danying Liao
Tags
macrophage recruitment
atherosclerosis
CCR2 silencing
EGFP-EGF1-conjugated nanoparticles
PLGA nanoparticles
gene therapy
targeted delivery
Related Publications
Explore these studies to deepen your understanding of the subject.